Proprietary programs
-
EP4R antagonist for immuno-oncology
-
mGluR4/7/8 positive allosteric modulator for Parkinson’s disease
-
NPFFR small molecule antagonist to combat the opioid crisis
-
PAR2 negative allosteric modulator for rare inflammatory diseases
-
First-in-class anti-GPCR antibody for immuno-oncology
-
MC4R pharmacochaperone for the treatment of early onset obesity